Prostate Cancer: Stages, Diagnosis, and Treatment

——————————————————————————–

About 1 in 8 American men will be diagnosed with prostate cancer in their lifetime, and the American Cancer Society estimates roughly 333,830 new U.S. cases and about 36,320 deaths in 2026, making it the most commonly diagnosed non-skin cancer in men. Yet the term covers a remarkable range of disease, from indolent tumors that men die with rather than from, to aggressive variants that demand prompt intervention. Prostate cancer management today rests on accurate staging, a clear understanding of risk groups, and treatment plans that balance survival benefit against quality-of-life trade-offs. This guide is educational; it is not a substitute for evaluation and individualized advice from your own urologist and oncology team, and none of it should be used to self-diagnose or delay care.

Understanding the Disease

Most prostate cancers are adenocarcinomas that arise in the peripheral zone of the gland. According to the National Cancer Institute, the lifetime probability of dying from prostate cancer is roughly 2.5 percent, much lower than the diagnosis rate, because many tumors are slow-growing. Five-year relative survival exceeds 97 percent across all stages combined and remains above 99 percent for localized and regional disease. However, survival drops sharply once the cancer has spread to distant sites, which is one reason the recent trend matters: the American Cancer Society reports that prostate cancer incidence has been rising by about 3 percent per year in recent years, with the steepest increases in advanced-stage diagnoses. The long decline in the prostate cancer death rate has also slowed, likely reflecting more cancers being found late. These trends are a major reason clinicians are re-emphasizing informed screening conversations.

Risk factors include age (most diagnoses occur after 65), African ancestry (incidence and mortality are notably higher in Black men), family history, and BRCA1/BRCA2 mutations. Lynch syndrome and HOXB13 mutations are rarer drivers. Diet, obesity, and inflammation may modify risk modestly. Men with a strong family history or known inherited mutations should discuss earlier and more frequent evaluation with their clinician.

Symptoms and Why Many Men Have None

Localized prostate cancer typically causes no symptoms, which is why screening exists. When symptoms occur they may overlap with BPH: urinary frequency, weak stream, hesitancy, and nocturia. Blood in the urine or semen, new erectile dysfunction, and pelvic pain warrant evaluation. Bone pain, unexplained weight loss, and fatigue can signal advanced disease that has spread to the spine, pelvis, or ribs. Because symptoms are unreliable and often absent, decisions about testing should be made proactively with a clinician rather than waiting for warning signs.

Screening and Shared Decision-Making

There is no single “everyone should be screened” rule, which is why screening is framed as a shared decision. The U.S. Preventive Services Task Force (USPSTF) recommends that men aged 55 to 69 make an individual decision about PSA-based screening after discussing the potential benefits and harms with their clinician, and it recommends against routine PSA screening in men 70 and older. Screening can reduce prostate cancer deaths for some men, but it also carries harms — false positives, additional testing and biopsies, and the diagnosis and treatment of cancers that would never have caused problems (overdiagnosis).

Specialty guidance complements this. The American Urological Association and Society of Urologic Oncology (AUA/SUO) early-detection guideline discusses offering a baseline PSA and beginning shared decision-making around age 45 to 50 for average-risk men, and earlier (roughly age 40 to 45) for men at higher risk based on Black race, germline mutations, or a strong family history, with repeat screening commonly every 2 to 4 years for men in their 50s and 60s. A newly elevated PSA is usually rechecked after a few months before any biopsy. Our prostate cancer screening guide covers this decision in more depth. The right choice depends on your age, health, values, and risk — and is best made with your own clinician.

How It Is Diagnosed

Diagnosis usually starts with an abnormal screening result, either an elevated PSA or a suspicious digital rectal exam. Multiparametric MRI of the prostate is now standard before biopsy in many practices; the PI-RADS score (1 to 5) estimates the probability of clinically significant cancer and helps decide whether — and where — to biopsy.

Suspicious lesions go to targeted biopsy, often combined with systematic 12-core sampling. Pathologists report findings using the Gleason Grade Group system: Group 1 (Gleason 6), Group 2 (3+4=7), Group 3 (4+3=7), Group 4 (Gleason 8), and Group 5 (Gleason 9-10). Higher groups predict more aggressive disease. Genomic tests on biopsy tissue can add prognostic information in selected cases.

Staging uses the TNM system. T1 tumors are clinically inapparent, T2 confined to the prostate, T3 extending through the capsule or into the seminal vesicles, and T4 invading adjacent structures. PSMA PET imaging, increasingly available, has improved detection of nodal and bone metastases compared with conventional CT and bone scan, particularly for higher-risk disease and biochemical recurrence.

Risk Stratification

NCCN risk groups combine PSA, Gleason Grade Group, and clinical stage. Very-low and low-risk disease (PSA under 10, Grade Group 1, T1c-T2a) often qualifies for active surveillance. Intermediate-risk splits into favorable and unfavorable based on the percentage of positive biopsy cores and Grade Group. High-risk disease (PSA over 20, or Grade Group 4-5, or T3a) usually warrants combination treatment. Very-high-risk and metastatic disease require systemic therapy from the outset. Risk group is the single biggest driver of which treatments are appropriate, which is why an accurate work-up matters so much.

Treatment Options

There is rarely one “correct” treatment. The options below all have roles depending on risk group, life expectancy, and personal priorities, and most men benefit from a multidisciplinary discussion before choosing.

Active Surveillance

For low-risk and many favorable intermediate-risk cancers, active surveillance avoids overtreatment. Patients undergo periodic PSA testing, repeat biopsies, and MRIs. The ProtecT trial showed comparable long-term prostate cancer mortality among surveillance, surgery, and radiation for localized disease, with quality-of-life advantages favoring surveillance early on. A meaningful share of men eventually convert to definitive treatment when monitoring shows progression.

Surgery

Radical prostatectomy, usually robot-assisted laparoscopic, removes the entire prostate and seminal vesicles. Common side effects include urinary incontinence (typically improving over 6 to 12 months) and erectile dysfunction. Nerve-sparing techniques can preserve potency in selected men with appropriate disease characteristics.

Radiation Therapy

External beam radiation, including IMRT, SBRT, and proton therapy, is delivered over days to weeks. Brachytherapy implants radioactive seeds (LDR) or temporary high-dose sources (HDR). Side effects include urinary irritation, bowel symptoms, and sexual dysfunction, often with a later onset than surgery. Radiation is sometimes combined with a period of hormone therapy for higher-risk disease.

Systemic Therapy

Androgen deprivation therapy (ADT) is the foundation for advanced disease, suppressing testosterone via GnRH agonists or antagonists. Modern androgen-receptor pathway inhibitors — including abiraterone, enzalutamide, darolutamide, and apalutamide — extend survival in metastatic and high-risk disease per landmark trials reflected in the NCCN guidelines. Chemotherapy with docetaxel and cabazitaxel remains important. PARP inhibitors (such as olaparib and rucaparib) help men with BRCA1/2 or other homologous recombination repair mutations, which is one reason genetic and genomic testing is increasingly recommended. PSMA-targeted radioligand therapy with lutetium-177 PSMA-617 (Pluvicto) targets PSMA-expressing metastases; in 2025 the FDA expanded its approved use to certain patients with metastatic castration-resistant prostate cancer earlier in the treatment course (after an androgen-receptor pathway inhibitor and before taxane chemotherapy), based on the PSMAfore trial. Pembrolizumab is an option for the small subset of tumors with high microsatellite instability or mismatch-repair deficiency. Which of these applies depends entirely on the individual’s disease and testing results.

When to See a Doctor

Men should discuss whether and when to screen with their primary care or urology provider — generally starting a conversation around age 50 for average risk, and earlier (around 40 to 45) for Black men, those with a first-degree relative diagnosed with prostate cancer, or known BRCA carriers. New urinary symptoms, blood in urine or semen, and unexplained bone pain deserve prompt evaluation at any age.

When to seek emergency care: Call 911 or go to the nearest emergency room if you experience sudden severe back pain with leg weakness or numbness (possible spinal cord compression from metastases), an inability to urinate, severe pelvic pain, or a fever above 100.4 degrees Fahrenheit during cancer treatment (a possible sign of infection while immunocompromised). These are urgent and should not wait for a routine appointment.

Frequently Asked Questions

Is all prostate cancer treated?

No. Many low-risk cancers are managed with active surveillance — monitoring rather than immediate intervention. This approach reflects the slow growth of most prostate adenocarcinomas and avoids the side effects of treatment for tumors that may never progress. Your care team helps decide whether surveillance is appropriate for you.

Does treatment always cause incontinence and ED?

Side effects vary by treatment, surgeon and center experience, patient anatomy, and pre-treatment function. Most men recover continence within a year of surgery; erectile recovery is more variable. Radiation tends to cause erectile dysfunction that develops gradually, sometimes peaking 1 to 2 years post-treatment. Ask your team about the specific risks for your situation.

What is PSMA PET and why does it matter?

Prostate-specific membrane antigen (PSMA) PET imaging detects prostate cancer cells with higher sensitivity than conventional imaging. It can change management in a meaningful share of patients, especially in biochemical recurrence and high-risk staging, and it also helps identify candidates for PSMA-targeted therapy.

Can prostate cancer be cured?

Localized disease has high cure rates with surgery or radiation. Metastatic disease is generally not curable but is often controllable for years with modern therapy, and some men live well over a decade with the disease. Outcomes depend heavily on risk group and individual factors.

How reliable is the PSA test?

PSA is useful but imperfect. It can be elevated by non-cancer causes such as BPH, infection, or recent activity, and it can miss some cancers. That is why an elevated PSA is usually confirmed with a repeat test and interpreted alongside exam findings, MRI, and, when appropriate, biopsy — not acted on in isolation.

What to Do Next

If you have an abnormal PSA or biopsy result, the most useful next step is a multidisciplinary consultation with a urologist, a radiation oncologist, and, when appropriate, a medical oncologist. Treatment decisions for prostate cancer are deeply individual, shaped by tumor risk, life expectancy, urinary and sexual function priorities, genetic and genomic findings, and access to advanced imaging and therapies. The right answer for one man is rarely the right answer for another — so use this guide to prepare questions, then make the decision with your care team. For related topics, see our medical conditions guide.